4-chloro-7H-pyrrolo[2,3-d]pyrimidine

4-chloro-7H-pyrrolo[2,3-d]pyrimidine serves as an important organic and pharmaceutical intermediate. As a key building block for Tofacitinib, it engages in nucleophilic substitution reactions to synthesize this JAK inhibitor, widely used for treating moderate to severe rheumatoid arthritis in adults with inadequate response to methotrexate.

Synonyms: 4-CHLORO-1H-PYRROLO(2,3-D)PYRIMIDINE; 4-CHLOROPYRROLO[2,3-D]PYRIMIDINE; 4-CHLORO-7H-PYRROLO[2,3-D]PYRIMIDINE; 6-CHLORO-7-DEAZAPURINE; 6-CHLORO-7-DEAZAPURINE 4-CHLORO-7H-PYRROLO[2,3-D]PYRIMIDINE 4-CHLORO-1H-PYRROLO[2,3-D]PYRIMIDINE 4-CHLOROPYRROLO[2,3-D]PYRIMIDINE 6-CHLORO-7-DEAZAPURIN; 4-Chloro-1H-pyrrolo[2,3-d]pyrimidine4-Chloropyrrolo[2,3-d]pyrimidine; 6-Chloro-7-deazapurin; 4-CHLORO-4H-PYRROLO[2,3-D]PYRIMIDINE

EINECS: 628-079-2

Product Categories: Fused Ring Systems; Heterocyclic Building Blocks; Heterocycle-Pyrimidine series; Baricitinib; Ruxolitinib; Tofacitinib; Heterocycles; Heterocycles series; Halides; Pyrimidine; Bases & Related Reagents; Intermediates; Nucleotides; Biochemistry; Nucleobases and their analogs; Nucleosides, Nucleotides & Related Reagents; CHIRAL CHEMICALS; Naphthyridine,Quinoline

Mol File: 3680-69-1.mol